Lyra Therapeutics   Report issue

For profit Phase 3
Founded: Watertown MA United States (2018)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2019
NCT04041609
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Lyra Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

mometasone (elocon) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chronic Disease (Phase 2)

Sinusitis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1